Ahmed Kotb, Hematologist and Bone marrow transplanter at King Faisal Specialist Hospital International Holding Company (KFSHI), shared a post on LinkedIn:
“Triplet Regimens in AML: Promises & Challenges.
IDH1/2-Mutated AML:
HMA+VEN+IDHi → 92% CRc, 2-year OS 82%
Low early mortality (30d: 0%, 60d: 2%)
FLT3-Mutated AML:
HMA+VEN+FLT3i →93% CRc, 82% MRD-ve, 41% SCT
Challenges:
Risk of myelosuppression & toxicity.”
